Harris A, Arend O, Arend S, Martin B
Department of Ophthalmology, Indiana University, School of Medicine, Bloomington, USA.
Acta Ophthalmol Scand. 1996 Dec;74(6):569-72. doi: 10.1111/j.1600-0420.1996.tb00737.x.
Topical carbonic anhydrase inhibitors such as dorzolamide have been developed as ocular hypotensive agents devoid of the side effects plaguing their systemic predecessors. We evaluated the influence of dorzolamide on retinal and retrobulbar blood flow markers to determine if the drug has orbital vascular as well as ocular hypotensive effects.
Eleven persons with healthy eyes received either placebo or two drops 2% dorzolamide, 2 h prior to studies conducted in double-masked, counterbalanced fashion. Four retrobulbar vessels (nasal and temporal posterior ciliary, central retinal, and ophthalmic arteries) were analyzed by color Doppler imaging; scanning laser ophthalmoscopy was used to examined retinal and superficial optic nerve head blood linear velocity.
Dorzolamide lowered IOP from 15.7 +/- 0.7 to 13.7 +/- 0.7 mmHg (p < 0.05). The drug also hastened retinal arteriovenous passage of fluorescein dye, and accelerated capillary dye transit in the macula and optic nerve head. The drug, however, left unaltered blood velocity or resistance index in any retrobulbar vessel.
Dorzolamide is an effective ocular hypotensive agent that accelerates blood velocity in the retinal and superficial optic nerve head without an apparent effect upon retrobulbar hemodynamics.
局部碳酸酐酶抑制剂如多佐胺已被开发为眼内压降低剂，没有困扰其全身应用前身的副作用。我们评估了多佐胺对视网膜和球后血流标志物的影响，以确定该药物是否具有眼眶血管以及降低眼压的作用。
11名眼睛健康的受试者以双盲、平衡的方式在研究前2小时接受安慰剂或两滴2%多佐胺。通过彩色多普勒成像分析四条球后血管（鼻侧和颞侧睫状后动脉、视网膜中央动脉和眼动脉）；使用扫描激光检眼镜检查视网膜和视神经乳头表面的血流线性速度。
多佐胺使眼压从15.7±0.7 mmHg降至13.7±0.7 mmHg（p<0.05）。该药物还加快了荧光素染料在视网膜动静脉的通过，并加速了黄斑和视神经乳头处毛细血管染料的转运。然而，该药物对任何球后血管的血流速度或阻力指数均无影响。
多佐胺是一种有效的眼内压降低剂，可加速视网膜和视神经乳头表面的血流速度，而对球后血流动力学无明显影响。
